Brawer et al., Cancer 75(7), pp. 1783-1789 (1995), “Chemoprevention for prostate cancer”. |
Presti, Jr., et al., J. Urology, vol. 148 (1992), pp. 1201-1204, “Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on Stage D prostate cancer”. |
Gormley et al., “A placebo controlled study of finasteride (MK-906) on Stage D prostate cancer”, abstract of talk given at the American Urol. Assoc. Mtg. in Jun. 1991 in Toronto, Canada. |
Gormley et al., Urologic Clinics of No. America, vol. 18, pp. 93-98 (1991), “Role of 5α-reductase inhibitors in the treatment of advanced prostatic carcnoma”. |
Gormley et al., “Effect of finasteride on serum PSA levels in men with prostate cancer”, at the Prostate Cancer 2nd Int'l Update in Denver, CO (Jan. 18, 1992). |
Huggins et al., Cancer Research, pp. 293-297 (1941), “Studies on Prostatic Cancer: I. Effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate”. |
Metcalf et al., TIPS, vol. 10, pp. 491-495 (1989), “Inhibitors of steroid 5α-reductase in benign prostatic hyperplasia, male pattern baldness and acne”. |
Kadohama et al., JNCI, vol. 71, No. 2, pp. 475-481 (1985), “Retardation of prostate tumor progression in the nobel rat by 4-methyl-4-aza-steroidal inhibitors of 5α-reductase”. |
Rainwater et al., Mayo Clinic Proc., vol. 65, pp. 1118-1126 (1990), “Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma”. |
Arai et al., J. of Urology, vol. 144, pp. 1415-1419 (1990), “Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer”. |
Hudson et al., J. of Urology, vol. 142, pp. 1011-1017 (1989), “Clinical use of prostate specific antigen in patients with prostate cancer”. |
Brawer et al., Supp. to Urology, vol. 33, No. 5, pp. 11-16 (1989), “Prostate-specific antigen in management of prostatic carcinoma”. |
Stamey et al., N. Eng. J. of Medicine, vol. 317, pp. 909-916 (1987), “Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate”. |
Walsh et al., Therapeutic Progress in Urological Cancers, pp. 27-33 (1989), “The value of prostate-specific antigen in the management of localized prostatic cancer”. |
Stamey et al., J. of Urology, vol. 141, pp. 1070-1075 (1989), “Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate”. |
Lange et al., J. of Urology, vol. 141, pp. 873-879 (1989), “The value of serum prostate specific angiten determinations before and after radical prostatectomy”. |
Hoehn et al., The Prostate, vol. 1, pp. 95-104 (1980), “Human prostatic adenocarcinoma: Some characteristics of a serially transplantable line in nude mice (PC 82)”. |
Brooks et al., The Prostate, 18:215-227 (1991), “Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the dunning rat prostatic carcinoma, R-3327”. |
J. of Andrology, vol. 12(6), pp. 372-375 (1991), “The MK-906 (Finasteride) Study Group: One year experience in the treatment of benign prostatic hyperplasia with finasteride”. |
Bologna et al., Current Therap. Res., vol. 51 (1992), “Antiandrogens and 5-alpha reductase inhibition of the proliferation rate in PC3 and DU145 hunan prostatic cancer cell lines” no copy. |
Lamb et al., The Prostate, vol. 21 (1992), pp. 15-34, “Response of rat and human prostatic cancers to the novel 5α-reductase inhibitor, SK & F 105657” no copy. |
Rasmusson et al., J. Med. Chem., vol. 29 (1986), pp. 2298-2315, “Azasteroids: Structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding” no copy. |
Tsukamoto et al., J. of the Nat'l Cancer Institute, vol. 87 (1995), pp. 842-843, “Chemoprevention of rat prostate carcinogenesis by use of fiansteride or casodex” no copy. |
Andriole et al., Urology, vol. 45 (1995), pp. 491-497, “Treatment with finasteride following radical prostatectomy for prostate cancer” no copy. |
Gormley et al., “Hormonal effects of finasteride in men with prostatic cancer after radical prostatectomy”, an abstract for presentation at Endocrine 1994 Society Meeting, Los Angeles, CA Jun. 1994 no copy. |
Carter et al., “Chemotherapy of Cancer”, 2nd ed., John Wiley & Sons, New York, NY (1981), pp. 3-10. |
Stedman, “Stedman's Medical Dictionary”, 24th ed. (1982), pp. 675-677. |